Mendelian randomisation identifies priority groups for prophylactic EBV vaccination

Mendelian randomisation identifies priority groups for prophylactic EBV vaccination

Abstract Background Epstein Barr virus (EBV) infects ~ 95% of the population worldwide and is known to cause adverse health outcomes such as Hodgkin’s, non-Hodgkin’s lymphomas, and multiple sclerosis. There is substantial interest and investment in developing infection-preventing vaccines for EBV. T...

Full description

Bibliographic Details
Main Authors: Marisa D. Muckian, James F. Wilson, Graham S. Taylor, Helen R. Stagg, Nicola Pirastu
Format: Article
Language:English
Published: BMC 2023-02-01
Series:BMC Infectious Diseases
Subjects:
Mendelian randomization
Epstein–Barr virus
Epidemiology
Public health
Vaccination
Online Access:https://doi.org/10.1186/s12879-023-08031-3

Internet

https://doi.org/10.1186/s12879-023-08031-3

Similar Items